In particular, current validated and established biomarkers for advanced and metastatic GC include human epidermal growth factor receptor 2 (HER2) expression via immunochemistry or in situ hybridization, programmed cell death ligand 1 (PD-L1) expression via immunochemistry and microsatellite instability [10]. This evidence concerns the gene ERBB2 and gastric cancer.